Navigation Links
NJ Docs Say Cancer Detection Tool Saves Lives
Date:10/10/2011

SHORT HILLS, N.J., Oct. 10, 2011 /PRNewswire/ -- The New Jersey Patient Care and Access Coalition (NJPCAC), representing more than 200 urologists in the Garden State, encourages men and their families to speak out to preserve prostate cancer screenings. Last week, the U.S. Preventive Services Task Force (USPSTF) recommended healthy men should no longer receive prostate-specific antigen (PSA) blood tests as part of routine cancer screening.

This decision was made by a panel that does not include a single urologist or oncologist. In fact, no new research has been cited that would call for this drastic change in prostate cancer testing recommendations since the USPSTF considered this issue just two years ago in 2009.

Newer studies have found that deaths from prostate cancer dropped 44 percent among screened men over a 14-year period, when compared with unscreened men, and found screening efficiency for prostate cancer similar to other cancers.

This is the same task force that suggested mammograms were unnecessary for women ages 40- 49 and recommended against teaching women breast self exams. That recommendation caused a public outcry and was soundly rejected by Congress.

The NJPCAC believes the USPSTF recommendations jeopardize the health of countless Americans and needlessly puts in harm's way the men who are most at risk: those who are underinsured, live in areas where health care is not readily available, have a family history of prostate cancer, and particularly African-Americans (who have the highest incidence of and death rates from prostate cancer). NJPCAC supports current recommendations endorsing PSA screening for well-informed men who wish to pursue early diagnosis.

"These recent recommendations by the government fail to protect our nation's health," said Dr. David Taylor, NJPCAC Chairman and President and President of Garden State Urology in Whippany. "There is no more important element to saving the lives of men who develop prostate cancer than early detection. These recommendations threaten to reverse two decades of progress in reducing deaths from prostate cancer. Even with our recent successes, prostate cancer is still the second leading cause of cancer death in men."

NJPCAC encourages all concerned citizens to contact policymakers to demand the government not restrict access to this life-saving testing.

About

The New Jersey Patient Care and Access Coalition (NJPCAC) was organized to promote and represent the common interests of urological care physicians in the State of New Jersey who are dedicated to the highest standards of practice and focused on addressing the challenges that confront our healthcare system.

NJPCAC's membership includes nearly 200 practicing urologists and scores of additional healthcare professionals, including radiation oncologists, pathologists, nurses and administrative staff, who have come together to educate policy makers, regulators, insurers and other key stakeholders, including patients and peers about legislative and regulatory changes that could adversely affect the quality and accessibility to care provided to patients in New Jersey and those that could advance care in New Jersey. Visit www.njpcac.org for more information about NJPCAC.

FOR MORE INFORMATION Donald Sico
dsiconj@gmail.com  
856-314-8066


'/>"/>
SOURCE New Jersey Patient Care and Access Coalition
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cancer Patients Can Benefit From Early Detection Of Heart Damage Using Echocardiography
2. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
3. New Research Shows PET Imaging Effective in Predicting Lung Cancer Outcomes
4. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
5. In Honor of National Breast Cancer Awareness Month, Alma Lasers Launches Nationwide Radiation Tattoo Removal Program, Declare Your Freedom
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
8. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
9. Media Alert: Elekta to Present $50,000 to Miami-Based Sandy B. Muller Breast Cancer Foundation at ASTRO Annual Meeting
10. Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
11. The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... ... cannabis market was worth an estimated $6.6 billion in 2016, and ... of 16% or reaching more than $24 billion by 2025. The ... 2025, or growing from $4.7 billion in 2016, to an estimated ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, ... in Europe for public health and the environment and is calling on the United ... and the overwhelming support of European citizens, the European Union (EU) will, beginning next ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex ... of “Profiling protein expression in circulating tumor cells using microfluidic western blotting” in ... of the Vortex technology to capture CTCs and a microfluidic single-CTC ...
(Date:3/22/2017)... ... 22, 2017 , ... Sam & Associates Insurance Agency, a ... related services to residents of the region, is embarking on a charity effort ... wild lands. , Endangered Species International is committed to ending the anthropogenic trends ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... consuming and frustrating and this tool bypasses that. Healthcare facilities across the ... an opportunity to offer their clients and hospitals, across the country, an efficient ...
Breaking Medicine News(10 mins):